Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
Funding Agency
Foreign For Profit
(Foreign-FP)
71.5M Funding
159 People
196 Grants
People
Buell Jannuzi
Astronomy
Department Head
Jeffrey Kingsley
Steward Observatory
Associate Director
Donata Vercelli
Cellular & Molecular Medicine
Professor
Ashley Michael
Asthma/Airway Disease Rsch Ctr
Research Technologist II
Oksana Pivniouk
Asthma/Airway Disease Rsch Ctr
Research Laboratory Manager I
Vadim Pivniouk
College of Medicine - Tucson
Associate Research Professor
Darren Cusanovich
Cellular & Molecular Medicine
Assistant Professor
Seongmin Hahn
Asthma/Airway Disease Rsch Ctr
Research Technologist II
Dayna Anderson
Asthma/Airway Disease Rsch Ctr
Research Technologist II
Kirsten Anderson
Az Health Sciences Division
Research Compliance Administrator IV
Recent Grants
A Phase I/II, Randomized, Double-blind, Sham Control Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Ascending Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gen
Active
·
2024
·
$1.1M
Komatsu Smart Control Jumbo Underground Proving
Active
·
2024
·
$495.6K
SOS-AMI Multi-Center, Double-Blind, Randomized , Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Self-Administered Subcutaneous Selatogrel for Prevention of All-Cause D
Active
·
2024
·
$447.6K
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures
Active
·
2024
·
$440.6K
A Double-Blind, Active-Controlled, Multiple-Ascending Dose Phase 1b Study of Aerosolized RSP-1502 Delivered Via the PARI LC Plus Nebulizer in Subjects with Cystic Fibrosis and Chronic Pseudomonas aeru
Active
·
2024
·
$306.4K
A Multi-Center, Phase IIA, Randomized, Double-Blind, Prospective, Active Placebo- Controlled Trial of Sub-Anesthetic Intravenous Infusion of Ketamine to Treat Levodopa- Induced Dyskinesia in Subjects
Active
·
2024
·
$303.6K
An Open-Label, Phase II, Randomized, Controlled Study of Danvatirsen Plus Pembrolizumab Compared to Pembrolizumab Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Active
·
2024
·
$275K
An Open-label, Controlled, Randomized Phase 3 Trial Evaluating 12-month Kidney Function in Highly Sensitized (cPRA > 99.9%) Kidney Transplant Patients With Positive Crossmatch Against a Deceased Donor
Active
·
2024
·
$246.8K
Feasibility of Fluciclovine PET/CT to Identify Brain Metastasis
Active
·
2024
·
$212.8K
Mechanisms of Action of Active Ingredients Used in Disinfectant Cleaning Products
Active
·
2024
·
$165K
